Epirus Biopharmaceuticals (EPRS) has agreed to become its partner for the development and future distribution of its lead product BOW015 for Latin American markets. As per the agreement, mAbxience will be responsible for regulatory submissions, using BOW015's existing data package, and eventual commercialization in Argentina, Chile, Ecuador, Paraguay, Uruguay, and Venezuela.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 26 | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- EPRSQ Stock
- News EPIRUS Biopharmaceuticals, Inc.
- Epirus Biopharmaceuticals Signs Up mAbxience as New Development, Distribution Partner for BOW015